ROS1 and non-small cell lung carcinoma: Overall, this study demonstrated that unecritinib had an acceptable safety profile and established the clinical benefit of unecritinib for ROS1 inhibitor-naive patients with ROS1-positive advanced NSCLC and other selected advanced solid tumors who had failed prior chemotherapy.